Volume 116, Issue 6, Supplement , Pages S13-S47, December 2005
The diagnosis and management of sinusitis: A practice parameter update
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology.
The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing “The diagnosis and management of sinusitis: a practice parameter update.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
Disclosure of potential conflict of interest: E. Wald has received grants from GlaxoSmithKline, MedImmune, and Sanofi Pasteur. F. Virant has received grants from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dey Labs, Genentech, GlaxoSmithKline, Hoffman LaRoche, Immunex, Key, Lederle, Lilly Research, Merck, Novartis, Pfizer, Purdue Fredrick, Sandofi, Schering, Sepracor, TAP Pharmaceuticals, 3M Pharmaceuticals, UCN Pharma, Upjohn Laboratories, and Med Point Pharmaceuticals; has consultant arrangements with NeoRex; and is on the speakers' bureau for GlaxoSmithKline, Aventis, Merck, Pfizer, Schering, AstraZeneca, and IDEC. S. Tilles has received grants from GlaxoSmithKline, Aventis, and Novartis and is on the speakers' bureau for GlaxoSmithKline, Aventis, and Pfizer. J. Oppenheim has consultant arrangements with Sepracor, GlaxoSmithKline, AstraZeneca, and Roche; has received grants from Boehringer Ingelheim, Schering, GlaxoSmithKline, Merck, Sepracor, AstraZeneca, Novartis and Altana; and is on the speakers' bureau for Sepracor, GlaxoSmithKline, AstraZeneca, Novartis, and Merck. D. Khan has consultant arrangements with Pfizer; has received grants from AstraZeneca; and is on the speakers' bureau for Merck, Pfizer, GlaxoSmithKline, and Aventis. D. Kennedy has consultant arrangements with Medtronic-Xomed and Schering-Plough; has received grants from Novartis; and is on the speakers' bureau for Merck. M. Kaliner has consultant arrangements with Aventis, Medpoint, Glaxo, Gasser, Adams, and King; has received grants from numerous pharmaceutical companies that are researching allergies; and is on the speakers' bureau for Aventis, Medpoint, GlaxoSmithKline, Gasser, and Abbot.Reprint requests: Joint Council of Allergy, Asthma and Immunology, 50 N Brockway St, #3-3, Palatine, IL 60067.
PII: S0091-6749(05)02254-2
doi:10.1016/j.jaci.2005.09.048
Volume 116, Issue 6, Supplement , Pages S13-S47, December 2005
